The buyer agreed to divest itself of several pharmaceutical assets to settle antitrust objections to its proposed $63 billion acquisition of Allergan.
( read original story …)
The SkinCare Site
The buyer agreed to divest itself of several pharmaceutical assets to settle antitrust objections to its proposed $63 billion acquisition of Allergan.
( read original story …)